Vaxinnate: A Small NJ Biotech Company with a Huge Mission

By Sara Lee Kessler

Vaxinnate, a nine-year-old New Jersey Biotech Company, has been awarded a 196-million-dollar federal contract to fund development of the next generation of flu vaccines.  Instead of using hens’ eggs, which takes six months, Vaxinnate relies on recombinant technology, using ecoli bacteria as a platform.  It’s much quicker.

Vodpod videos no longer available.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s